Manitou BF (0NDA) Share Forecast & Price Target
0NDA Analyst Ratings
There are no analyst ratings in the last 3 months.
0NDA Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Auguste Deryckx Lienart | Kepler Capital | EUR 20 | hold | -0.25%Downside | Reiterated | 04/29/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Auguste Deryckx Lienart | 04/29/26 | EUR 20 | hold | -0.25%Downside | Reiterated | Kepler Capital |
Best Analysts Covering Manitou BF
Copying OpenAI General GB's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -13.10% per trade.
Copying OpenAI General GB's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -13.10% per trade.
Copying OpenAI General GB's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -13.10% per trade.
0NDA Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 0 | 0 | 0 | 0 |
In the current month, 0NDA has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 0NDA average Analyst price target in the past 3 months is ―.
0NDA Financial Forecast
0NDA Earnings Forecast
Next quarter’s earnings estimate for 0NDA is EUR 1.34 with a range of ― to ―. The previous quarter’s EPS was EUR 1.34. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
0NDA Sales Forecast
Next quarter’s sales forecast for 0NDA is EUR 1.43B with a range of ― to ―. The previous quarter’s sales results were EUR 1.43B. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.
